In the case of Mylan the problem is not the drug which is unbelievably cheap, but the medical device surrounding the drug. (the autoinjector) Mylan has patents

In the case of Mylan the problem is not the drug which is unbelievably cheap, but the medical device surrounding the drug. (the autoinjector) Mylan has patents on the design of the epipen that don't expire until 2025. Other devices such as the auvi-q were taken off the market due to inconsistent dosages being administered.